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Abstract: Erectile dysfunction (ED) is a problem that may affect up to 52% of men between 
the ages of 40 and 70. It can be distressing because of its negative effect on self-esteem, quality 
of life, and interpersonal relationships. Oral phosphodiesterase-5 inhibitors (PDE5 inhibitors) 
are now the ﬁ  rst choice of treatment in ED. The availability of three (sildenaﬁ  l citrate, tadalaﬁ  l, 
and vardenaﬁ  l) well tolerated and effective oral PDE5 inhibitors gives treatment options for 
men with ED. Although the mechanism of action is the same for the three drugs, they differ 
in their pharmacokinetics. Several preference studies were conducted between the three PDE5 
inhibitors but they were not free from bias. Because of the lack of overwhelming reliable data 
showing that one PDE5 inhibitor is superior to another, current opinion is that the individual 
patient should have the opportunity to test all three drugs and then select the one that best suits 
him and his partner.
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Introduction
Erectile dysfunction (ED) is deﬁ  ned as the consistent or recurrent inability to attain 
and/or maintain an erection sufﬁ  cient for sexual performance.1 ED has an overall 
prevalence of 52% in men between the ages of 40 and 70. Of these 52%, 17.2% have 
minimal ED, 25.2% have moderate ED while 9.6% have severe ED.2 The incidence of 
ED increases with age; however, it is important to remember that it is not an inevitable 
consequence of aging and that advancing age does not preclude sexual interest. With 
increasing life expectancy, it is anticipated that the prevalence of ED will rise.3
ED can be distressing because of its negative effect on self-esteem, quality of life, 
and interpersonal relationships. Erectile function is a key quality of life indicator for 
many men. Men with ED may endure diminished self-image and self-esteem, anxiety 
and fears of rejection, and even depression.4,5 The female partner may also suffer from 
female sexual dysfunction secondary to her partner’s ED.6
The etiology of erectile dysfunction can be divided into psychological and physical 
factors although in most cases both mechanisms interplay. Psychological factors include 
depression, relationship issues, sexual ignorance, fear of failure, performance anxiety, 
and childhood or adult sexual abuse. Physical or organic ED may be vasculogenic 
as in diabetes, hypertension, hypercholesterolaemia and smoking, neurogenic as in 
spinal injuries, endocrinal as in hypogonadism and hypothyroidism, and local penile 
tissue factors as in Peyronie’s disease. Recent studies have shown the association of 
ED with metabolic syndrome and cardiovascular disease. ED is now considered a 
marker for these conditions and consequently the management of ED now concentrates Patient Preference and Adherence 2009:3 100
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on screening for, and preventing, cardiovascular diseases as 
well as treating the ED itself.7
Oral phosphodiesterase-5 inhibitors (PDE5 inhibitors) are 
now the ﬁ  rst choice of treatment in ED due to their efﬁ  cacy 
and safety and the fact that they are non invasive.8
In the era of PDE5 inhibitors the treatment of ED can be 
simple, effective and with good response rates. Other lines of 
therapy such as intracorporal or penile implants are resorted to 
in patients who fail to respond to PDE5 inhibitors. The patient-
oriented approach for diagnosis and treatment of ED is the 
preferred approach for the majority of men. This means that 
medical history, psychosexual history, physical examination 
and basic laboratory investigations are done for all patients 
while other investigatory modalities are reserved for selected 
cases.9 Following the initial assessment patients should have 
the available treatment options explained, including the 
beneﬁ  ts and the potential complications of each modality. 
The treatment plan is thus formulated jointly between the 
physician and patient. Where possible, the patient’s partner 
should also be involved, taking into consideration the patient’s 
preferences, concerns and expectations.10,11 This allows the 
formulation of a treatment plan which can be tailored to the 
needs and lifestyle of an individual patient.
The availability of three well tolerated and effective 
oral PDE5 inhibitors gives treatment options for men with 
ED. A patient’s preference for an ED therapy is determined 
mainly by its efﬁ  cacy, tolerability and safety. However other 
factors are also involved and they depend on the patient and 
his partner’s expectations from the treatment and its overall 
effect on the quality of their sex life.
Mechanism of action 
of PDE5 inhibitors
Erection is a hemodynamic phenomenon mediated via the 
nitric oxide (NO)-cyclic guanosinemonophosphate (cGMP) 
pathway. Following sexual stimulation, neuronal impulses 
cause the release of NO into the corpora cavernosa. cGMP acts 
as a second messenger for NO, causing smooth muscle relax-
ation leading to increased arterial blood ﬂ  ow and sinusoidal 
relaxation which in turn causes compression of the veins 
preventing venous return, and erection occurs. Phosphodi-
esterase PDE5 is an enzyme that breaks down cGMP. PDE5 
inhibitors act as competitive inhibitors of PDE5 thus helping 
erection.12
Pharmacokinetics of the three 
PDE5 inhibitors
As competitive inhibitors of PDE5, PDE5 inhibitors have 
structures derived from cGMP. Sildenaﬁ  l and vardenaﬁ  l 
have very similar molecular structures. In contrast, tadala-
ﬁ  l has a different chemical structure from sildenaﬁ  l and 
vardenaﬁ  l. These structural differences lead to differences 
in the pharmacokinetics of the three drugs.13
The mean time to maximum plasma concentration of 
sildenaﬁ  l and vardenaﬁ  l is 1 h and for tadalaﬁ  l is 2 h, while the 
half-lives of sildenaﬁ  l and vardenaﬁ  l are 4 h and that of tadalaﬁ  l 
is 17.5 h. Food high in fat delays and reduces the absorption 
of sildenaﬁ  l and vardenaﬁ  l, but does not affect the rate or 
extent of absorption of tadalaﬁ  l.15 These pharmacokinetics 
give tadalaﬁ  l the advantage of allowing spontaneity in sex and 
giving the couple an open window for successful intercourse, 
making it different from the other two PDE5 inhibitors.
Drug interactions of the three 
PDE5 inhibitors
All PDE5 inhibitors act via the NO/cGMP mechanism thus 
they can have synergistic effects when used with nitrates or 
NO donors causing sever hypotension. All PDE5 inhibitors 
are broken down mainly via cytochrome P450 thus a dose 
adjustment should be considered when given in combination 
with cytochrome P450 inhibitors like HIV protease inhibitors, 
erythromycin and ketoconazole as these drugs may inhibit 
PDE5 inhibitor plasma clearance and potentiate its effect.16
Efﬁ  cacy of the three PDE5 
inhibitors
All three PDE5 inhibitors have been shown to be effective 
and safe in the broad population of men with ED as well as 
Table 1 Pharmacokinetics of the three PDE5 inhibitors14
Drug Tmax (h)a Earliest onset 
of action (min)
T1/2 (h)b Duration of effect (h) Recommended dosing time (h) 
prior to intercourse
Sildenaﬁ  l 100 mg 1 30 4 4–6 (up to 12) 1
Tadalaﬁ  l 20 mg 2 20 17.5 24–36 (up to72) 0.5–12
Vardenaﬁ  l 20 mg 0.7 10 4.5 5–7 (up to 12) 0.5–1
aTmax time needed to reach maximum plasma concentration (Cmax ), which corresponds to onset of action.
bT1/2 half-life, which corresponds to duration of efﬁ  cacy.Patient Preference and Adherence 2009:3 101
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different subpopulations.17 Patients who fail to respond to one 
PDE5 inhibitor may respond to other PDE5 inhibitors.18 Fail-
ure on a PDE5 inhibitor should not be considered before at 
least 8 failures to respond to maximum dose medications.19,20 
Daily dosing with PDE5 inhibitors for several months in 
previous PDE5 inhibitor non-responders may rescue more 
than 50% of patients.21,22 Treatment of concomitant diseases, 
eg, diabetes, hyperlipidemia and treatment of hypogonad-
ism can improve erectile function and response to PDE5 
inhibitors.23–25
Side effects of the three 
PDE5 inhibitors
Side effects occur due to vasodilatation elsewhere in the body 
caused by inhibition of other phosphodiesterase enzymes. 
Side effects are similar for the three drugs and include 
headache, ﬂ  ush, dyspepsia and rhinitis, with the exception 
of visual disturbances which occur with sildenaﬁ  l and back 
pain which occurs with tadalaﬁ  l. Generally these side effects 
are mild to moderate and resulted in 1%–2% drop outs in 
clinical trials.17
Precautions and contraindications 
of PDE5 inhibitors
Because PDE5 inhibitors act in a similar way via the NO/
cGMP mechanism, the contraindications are similar for the 
three drugs. Patients with poor general condition, eg, severe 
cardiovascular disease, for whom sexual activity may be 
risky should not be given ED treatment. In patients receiv-
ing nitrate or NO-donors, treatment with PDE5 inhibitors 
is contraindicated because they act via the same NO/cGMP 
mechanism and concomitant treatment with a PDE5 inhibitor 
can lead to severe hypotension and shock.26
Howeversome of the patients with stable coronary heart 
disease and erectile dysfunction currently taking oral long-
acting nitrates can be withdrawn from this treatment without 
facing disadvantages and can then be successfully treated 
with a PDE5 inhibitor.27
Rare reports of sudden loss of vision due to non-arteritic 
anterior ischemic optic neuropathy (NAION) led the FDA 
to update the labels of all three products. The labels now 
advise doctors to stop PDE5 inhibitor therapy in the event 
of sudden loss of vision in one or both eyes and to discuss 
the increased risk of NAION in patients who have already 
experienced NAION. At present, however, it is not possible 
to determine whether these events were related to PDE5 
inhibitors or to other factors.15 Conditions predisposing to 
NAION are: age 50, heart disease, diabetes, hypertension, 
high cholesterol, smoking and certain eye problems.17
There are certain precautions when using PDE5 inhibi-
tors in patients taking α-blockers due to the possibility of 
symptomatic hypotension with concomitant use. Sildenaﬁ  l, 
vardenaﬁ  l and tadalaﬁ  l could be used with caution only in 
patients stabilised on the α-blocker therapy. Furthermore 
the PDE5 inhibitors should be initiated at the lowest recom-
mended dose.28–30 However one study showed that tadalaﬁ  l 
had no clinically signiﬁ  cant effect on blood pressure changes 
caused by tamsulosin.31
Patient preference
Clinical decision making is based on many factors. Some 
clinicians will claim to rely solely on research evidence, 
others their own clinical experience, but will consciously or at 
least subconsciously be affected by their own value systems. 
The availability of three, well tolerated and effective oral 
PDE5 inhibitors gives physicians treatment options for men 
with ED. The treatment of ED is unlike most other ﬁ  elds of 
medicine in that the outcome of treatment is not based on a 
laboratory result and cannot be measured by radiology, but 
Table 2 Side effects of PDE5 inhibitors17
Side effect Sildenaﬁ  l Vardenaﬁ  l Tadalaﬁ  l
Headache 14.6% 14.5% 14%
Flush 14.1% 11.1% 4%
Dyspepsia 6.2% 3.7% 10%
Rhinitis 2.6% 9.2% 5%
Back pain 0% 0% 6%
Visual disturbances 5.2% 0% 0%
Research Evidence
Clinical Experience Preferences,
Values, and Rights
Figure 1 How decisions are made in clinical practice.Patient Preference and Adherence 2009:3 102
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is based solely on the judgment of the patient. Hence the 
“best” treatment for patients can really be judged only by the 
patients themselves and their partners. Some of the issues 
that affect choice are listed below.
Following the release of vardenaﬁ  l and tadalaﬁ  l several 
preference studies were conducted for the three PDE5 inhibi-
tors. Many of these studies showed that patients preferred 
tadalaﬁ  l. However these studies were criticized for their design 
and contradictory results. Studies from the industry tend to 
show preference for their own drug, whereas independent 
studies tend to show no major difference in preference.32
In a double-blind crossover study between tadalaﬁ  l 20 mg 
and sildenaﬁ  l at a ﬂ  exible dose, of the 181 who completed the 
study, 73% preferred tadalaﬁ  l for the extension period.33
An open-label, one-way crossover trial involved patients 
on sildenaﬁ  l and consisted of a 1-week screening phase, 
a 3-week sildenaﬁ  l assessment phase, a 1-week washout 
phase, a 6-week tadalaﬁ  l initiation phase, a 3-week tadalaﬁ  l 
assessment phase, and a 6-month extension phase, during 
which patients received their treatment of choice free of 
charge. Of the 147 men who completed the trial, 133 (90.5%) 
chose tadalaﬁ  l and 14 (9.5%) chose sildenaﬁ  l.34
In another open-label multicenter study, men who were 
taking sildenaﬁ  l at doses of  25–100 mg tested tadalaﬁ  l 20 mg 
for 8 weeks. Of the 2453 men, 82% preferred tadalaﬁ  l. 
The main factors inﬂ  uencing this choice were an improvement 
in timing concerns and in sexual self conﬁ  dence. Patients who 
took 2.5 sildenaﬁ  l doses per week or high doses of sildenaﬁ  l 
had a greater likelihood of remaining on sildenaﬁ  l.35
Similarly, in a recent open-label European multicenter 
preference study between sildenaﬁ  l and tadalaﬁ  l involving 
patients naïve to PDE5 inhibitor therapy, patients were 
randomized to receive sildenaﬁ  l for 12 weeks followed 
by tadalafil for 12 weeks or vice versa. Each 12-week 
period included an 8-week dose optimization phase and a 
4-week assessment phase and 7–10 days’ washout. Patients 
completing the study then got to choose which treatment 
to continue on for an 8-week extension phase. A total of 
294 men completed the study; 29% (n = 85) chose sildenaﬁ  l 
for the extension phase and 71% (n = 206) chose tadalaﬁ  l. 
The patient’s preference was not affected by treatment 
sequence, ED severity or etiology, age, or dosage. Both drugs 
were found effective and safe.36
In contrast, in an independent study involving PDE5-
naïve patients, 418 patients tested each PDE5 inhibitor at 
least 4 times. There was no difference in patient prefer-
ence or in the drug-induced international index of erectile 
function score increase between the three drugs. However, 
young men with mild dysfunction preferred tadalaﬁ  l, while 
older men, with more severe ED, preferred sildenaﬁ  l or 
vardenaﬁ  l.37
Other studies tried to detect patient preference indirectly 
by monitoring prescription data. An analysis of prescription 
data from 40,000 pharmacies in the US showed that men who 
are prescribed sildenaﬁ  l as an initial treatment for ED are less 
likely to switch to another PDE5 inhibitor than those who 
are initially prescribed vardenaﬁ  l or tadalaﬁ  l.38 Another study 
from the UK analyzed the prescription data of 2703 patients 
who initiated treatment for ED with a PDE5 inhibitor. Results 
showed that patients who were initially prescribed sildenaﬁ  l 
are less likely to switch to another PDE5 inhibitor than those 
who were initially prescribed tadalaﬁ  l or vardenaﬁ  l. Patients 
who were initially prescribed tadalaﬁ  l or vardenaﬁ  l were 
nearly 4 times more likely to switch PDE5 inhibitors than 
patients who were initially prescribed sildenaﬁ  l.39
In an evaluation of preference studies conducted for 
PDE5 inhibitors, Mulhal and Montorsi40 concluded that the 
studies had design defects which cause bias, sources of which 
included: not using a randomized, double-blind, crossover 
design, period effect (which involves adaptation to treat-
ment so that the results will be in favor of the second drug, 
and may also occur due to unequal treatment periods), and 
carryover effect (the effect of the ﬁ  rst treatment used may 
carry over to the next treatment, making the second treatment 
seem more effective than the ﬁ  rst; it is a strong element of 
bias in trials where a single drug sequence is used). Other 
factors include the amount of time allotted for each medica-
tion, the amount of study drug, the dose of study drug, the 
instructions that accompany each drug (which all have to be 
Medication issues
• Efficacy
• Safety
• Tolerability
• Duration of action
• Food interactions 
• Reputation
• ‘Newness’
• Cost
Patient issues
• Marital status
• Culture
• Finances
• Comorbidity
• Expectations
Physician 
issues
• Experience
• Familiarity
• Expertise
Figure 2 Factors affecting preference for a PDE5 inhibitor.Patient Preference and Adherence 2009:3 103
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the same for the studied drugs to avoid bias); sufﬁ  cient time 
should be left between drugs for washout of any previous 
period or carryover effects. The selection criteria were also a 
source of bias in some trials in which vardenaﬁ  l and tadalaﬁ  l 
patients who had been previously treated successfully with 
sildenaﬁ  l were included, but non responders or patients who 
had experienced severe side effects were excluded. This bias 
increased efﬁ  cacy and decreased side effects for these drugs. 
Moreover, drug preference assessments should not wait until 
the end of the study and should not favor a particular drug. 
A questionnaire that covers efﬁ  cacy, safety, and reasons 
for preference should be used. All preference data should 
be analyzed using the intent-to-treat group; for example, if 
discontinuations are the result of a treatment effect, analyses 
that include only study completers will overestimate treat-
ment preference.
A well-designed crossover trial that assesses safety, 
efﬁ  cacy and patient preference for all three PDE5 inhibitors 
has not yet been reported.39 Because of the lack of over-
whelmingly reliable data showing that one PDE5 inhibitor 
is superior to another, current opinion is that the individual 
patient should have the opportunity to test all three drugs and 
then select the one that best suits him and his partner.32
This opinion was supported by an independent Swedish 
study14 in which patients were offered the opportunity to 
try the maximum dose of 8 short-acting tablets (4 tablets 
100 mg sildenaﬁ  l and 4 tablets 20 mg vardenaﬁ  l) and 8 
long-acting tablets (20 mg tadalaﬁ  l). Among the 138 patients 
who responded to treatment and completed the trial there 
was no signiﬁ  cant difference between those who preferred 
a long-acting drug (tadalaﬁ  l, 55%) and those who preferred 
a short-acting drug (44%: sildenaﬁ  l, 27%; vardenaﬁ  l, 17%). 
Moreover 19% of the patients requested a combination of 
both short- and long-acting drugs to accommodate their 
needs. Naïve patients preferred a short-acting drug while 
previously treated patients preferred a long-acting drug. 
Patients with mild ED tended to prefer a long-acting drug, 
but there was no difference in preference related to age or 
cause of ED. For patients preferring a short-acting drug, the 
primary reason was efﬁ  cacy (82%), few side effects (15%) 
and rapid onset (3%). For patients preferring a long acting 
drug, the primary reason was the long duration of effect 
(96%) and few side effects (4%).
Conclusion
Since the introduction of sildenaﬁ  l citrate, PDE5 inhibi-
tors have become the ﬁ  rst line treatment for ED owing to 
their efﬁ  cacy, safety and the fact that they are non invasive 
compared with other treatments. Following the introduction 
of tadalaﬁ  l and vardenaﬁ  l several patient preference studies 
were conducted; however, because they were not free from 
bias there are insufﬁ  cient data for the clinician or the patient 
to judge which PDE5 inhibitor is superior. A good regimen is 
to allow the patient try all three PDE5 inhibitors and choose 
which best suits him and his partner. This regimen will also 
result in a higher success rate to PDE5 inhibitor therapy. 
Moreover some patients may prefer a combination of short- 
and long-acting PDE5 inhibitors.
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